Precision Medicine in Community Oncology

Most oncology strategies are shaped by evidence and infrastructure that is built and measured in academic centers. Yet most patients are treated in community oncology settings, where biopsy timing, tissue adequacy, turnaround time for molecular results, payer utilization management and social determinants of health (SDOH) can determine whether precision medicine is delivered consistently.

This nine-slide deck asks the readiness questions every life sciences team working in oncology should be able to answer. Does your evidence plan reflect how community oncology actually works? Which test answers the clinical question — NGS panel, focused assay or liquid biopsy? Can ordering and interpretation hold together across multidisciplinary teams? What do payer requirements do to your timeline from result to treatment? And are social determinants of health measured, or treated as background?

It closes with three ideas from a community test-to-treat playbook: the real-world levers of precision oncology uptake, testing chosen well and SDOH as measurable factors.

There is far more to the test-to-treat story than fits in nine slides. Go deeper in the free Xtalks webinar "Improve Precision Medicine Timelines in Community Oncology Care," which aired June 4, 2026 — the full 60-minute recording is available on demand with free registration. Webinar attendees will learn the real-world levers that determine precision oncology uptake in community settings, how measurable SDOH factors change outcomes and evidence plans in underserved community cohorts undergoing advanced genomic testing and executive decisions about liquid biopsy implementation, inclusive evidence generation and scalable access strategies for therapies and diagnostics.

Register free to watch the recording on demand:
https://xtalks.com/webinars/improve-precision-medicine-timelines-in-community-oncology-care/?utm_source=slideshare&utm_medium=promodeck

Transcript

1. X TA L K S — T H E L I F E S C I E N C E C O M M U N I T Y ™ YGOLOCNO NOISICERP Bring Precision Medicine to Where Most Patients Are Treated Evidence is built in academic centers. Care mostly happens in If your life science strategy the community, where timing, tissue and payer requirements assumes an academic center, how decide whether precision medicine is actually delivered. well does it hold up in the community?
2. 01 — THE SHIFT Most Patients Are Treated Where the Evidence Is Not Built Oncology strategies are shaped by evidence built and measured in academic centers. Most patients, though, are treated in community oncology settings. 02 / 09 Learn more in this webinar →
3. 02 — READINESS CHECK Does Your Evidence Plan Reflect How Community Oncology Actually Works? Biopsy timing, tissue adequacy, turnaround time and payer requirements all sit between a biomarker result and a treatment decision. T O D AY THE TEST Whether precision medicine is delivered consistently can come down to timing, tissue and turnaround. Could your team choose the right test, coordinate interpretation and turn results into treatment action? 03 / 09
4. 0 3 — T H E G A P, I N O N E N U M B E R Most patients Community oncology is the main event, not the edge case. are treated in community oncology settings, not the academic centers where evidence is built Biopsy timing, tissue adequacy, turnaround time and payer requirements can determine whether precision medicine is delivered consistently. 04 / 09
5. 04 — THE DILEMMA One Playbook, Four Community Realities TESTING Which test answers the question — NGS panel, focused assay or liquid biopsy? W O R K F LO W Can ordering and interpretation hold together across multidisciplinary teams? ACCESS What do payer requirements do to your timeline from result to treatment? PAT I E N T S Are social determinants of health measured, or treated as background? 05 / 09
6. 05 — THE TURN From Test Results to Treatment Action A biomarker result only matters if it changes what happens next. The question is what it takes to make that true at community scale. 06 / 09
7. 0 6 — W H AT Y O U ' L L TA K E AW AY What a Community Test-to-Treat Playbook Covers 01 The Real-World Levers Workflow, turnaround time, payer requirements and referral networks shape precision oncology uptake in ways academic-center assumptions miss. 02 Testing, Chosen Well Tumor NGS panels, focused assays, germline testing and liquid biopsy each answer different questions. Matching test to question is the craft. 03 SDOH as Measurable Factors Social determinants of health shape outcomes, access and evidence feasibility. Treating them as measurable factors changes the plan.
8. Most oncology strategies are shaped by evidence and infrastructure that is built and measured in academic centers. Where evidence comes from shapes what strategies assume. The open question is what changes when the community setting leads. These nine slides are only the introduction. There is far more to the test-totreat story than fits here. 08 / 09
9. G O D E E P E R — F R E E X TA L K S W E B I N A R Improve Precision Medicine Timelines in Community Oncology Care Aired June 4, 2026 · 60 min · recording available on demand W E B I N A R AT T E N D E E S W I L L L E A R N : The real-world levers that determine precision oncology uptake in community settings and how they differ from academic-center assumptions How measurable SDOH factors Register free to watch the full recording on demand. See how a change outcomes and evidence community oncology test-to-treat playbook can strengthen biomarker plans in underserved community testing, treatment action and evidence strategies at scale. cohorts undergoing advanced genomic testing Executive decisions about liquid REGISTER FREE biopsy implementation, inclusive evidence generation and scalable xtalks.com/webinars/improve-precision-medicine-timelines-in-community-oncology-care access strategies for therapies and diagnostics